Vita Therapeutics and I Peace Join Forces to Deliver Gene-Edited Stem Cells for Muscular Dystrophy
The companies will collaborate to leverage gene editing and GMP iPSC manufacturing to hopefully deliver new therapies.
Hope Biosciences Launches Phase Ib/IIa Stem Cell Trial for Early Alzheimer’s Disease
Hope Biosciences will study whether stem cell therapy can reduce inflammation or slow Alzheimer’s progression in a new clinical trial.
FDA Grants Orphan Drug Designation to KLTO-202 Gene Therapy for ALS Treatment
Klotho Neurosciences’ gene therapy is advancing plans for ALS clinical trials next year.
Stem Cell and Spinal Stimulation Trial for Chronic Spinal Cord Injury
The study will test whether combining umbilical cord stem cells and spinal cord stimulation can safely help people with chronic spinal cord injury.
New Trial: iPSC-Derived Exosome Therapy for Moyamoya Disease
Researchers are testing whether exosomes from stem cells can enhance blood vessel repair for Moyamoya patients after surgery.
Intranasal Stem Cell Therapy: A Nasal Gateway to the Brain Shows Promise for CNS Diseases
For decades, treating diseases of the central nervous system (CNS) with stem cells has been hampered by one persistent biological obstacle: the blood–brain barrier (BBB). While the BBB protects the brain from harmful substances, it also blocks most drugs and…
FDA Reevaluating ALS Stem Cell Data following Citizen Petition – NurOwn from BrainStorm Cell Therapeutics
The FDAs new faces are feeling the pressure from patients and advocates on speeding up potential ALS therapies
NurExone reports enhanced scalability and clinical readiness for upcoming exosome-based clinical trials for neurological conditions
The Israeli regenerative medicine company is moving one step closer to clinical trials for serious neurological indications such as TBI, spinal cord injury, etc.
BrainStorm’s ALS stem cell treatment reports 90% survival over 5 years in expanded access program
BrainStorm's NurOwn, its ALS candidate stem cell therapy, has shown significantly higher five-year survival rates compared to expectations in a small 10 participant program.
UniXell Biotechnology doses first Parkinson’s patient with iPSCs, reports improvements
The Chinese biotech company reports that the patient showed notable improvements in sleep quality and motor function, with no serious adverse events.
Trailhead Biosystems launches iPSCs for blood-brain barrier and neurological research
Researchers may now have a new tool to unlock insights into blood-brain barrier regulation and neurological disease mechanisms.
TreeFrog Therapeutics nabs €30M in funding to accelerate its iPSC technology, planning Parkinson’s trial in 2027
TreeFrog has developed a proprietary iPSC manufacturing process called C-Stem, moving one step closer to human trials.
Stem cell exosomes for spinal cord injury: Preclinical study shows improved motor function and blood flow
NurExone Biologic's exosome product moves one step closer to clinical trials with their latest data, published in Cyotherapy.
Parkinson’s stem cell trial launches: Aspen Neuroscience doses first patient with iPSCs
A new milestone for iPSC therapy in the USA, this is one to watch.
New Study: Intrathecal Umbilical Stem Cells + Transcutaneous Stimulation for Spinal Cord Injury
The neurorehabilitation hospital in Spain will investigate if allogeneic umbilical-derived stem cell therapy can help enhance recovery.
BrainChild Bio granted FDA RMAT designation for its CAR T-cell therapy for incurable pediatric brain tumors
The company plans on moving to Phase 2 later this year, hopefully supporting a BLA in the near future.
iPSC-Derived Motor Neuron Cells’ Dose Escalation Trial for Subacute Spinal Cord Injury, a Phase I
This study will evaluate if allogeneic human induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cells (XS228, made by XellSmart) can safely and effectively treat subacute spinal cord injury. Researchers at the Third Affiliated Hospital, Sun Yat-Sen University, in collaboration…
ALS Stem Cell Trial: Efficacy and Safety of NurOwn in Early & Moderate ALS (ENDURANCE STUDY)
Brainstorm Therapeutics is back, and they've learned a lot from their previous trials. If you don't know the history of Nurown, their ALS stem cell candidate, it showed early promise in Phase 2 with some slowed disease progression. In Phase…
Lineage Cell Therapeutics’ Spinal Cord Injury Stem Cell Trial, New Delivery Device
The new DOSED trial will explore a novel delivery method for OPC1 cells, potentially bringing hope to chronic SCI patients.
Stem cell trial for early Alzheimer’s disease to begin at UTHealth Houston, will use Hope Biosciences’ technology
Will adipose stem cell therapy hold an answer for neuroinflammation, a factor in Alzheimer's?
Phase III Stem Cell Trial for Epilepsy Launching This Year from Neurona Therapeutics
This follows their RMAT designation, and promising Phase 1/2 trial results, which they presented earlier this year.
FDA approves new nerve repair product from Orthocell
With FDA approval now secured, Orthocell prepares to launch Remplir into the lucrative US nerve repair market, accelerating commercialisation.
Chinese stem cell (iPSC) therapies receive Phase I trial clearance for ALS & Parkinson’s
They'll be using allogeneic iPSCs to treat neurodegenerative disorders. ALS stem cells can be a tough topic after the Nurown trials... are iPSCs the answer?
BrainStorm Cell Therapeutics Gearing Up for Phase 3b Trial of NurOwn, Its ALS Stem Cell Therapy, Submits IND Amendment
The amended IND application moves NurOwn® closer to initiation of the pivotal Phase 3b clinical trial for ALS patients.
Cellino and Matricelf Partnering to Scale Stem Cells for Spinal Cord Injury
Cellino has successfully manufactured and delivered patient-specific autologous induced pluripotent stem cell (iPSC) lines from four donors to Matricelf for spinal cord injury treatment.